Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: A pilot study

American Journal of Nephrology

Volumn 36, Issue 3, 2012, Pages 238-244

  Mitsopoulos, Efstathios ^a   Ginikopoulou, Eudoxia ^a   Economidou, Dominiki ^b   Zanos, Stavros ^c   Pateinakis, Panagiotis ^a   Minasidis, Elias ^a   Memmos, Dimitrios ^b   Thodis, Elias ^d   Vargemezis, Vassilis ^d   Tsakiris, Dimitrios ^a  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Bisphosphonates; Bone mineral density; Calcimimetics; Chronic hemodialysis; Osteoporosis; Renal osteodystrophy; Teriparatide

Indexed keywords

CINACALCET; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

ADULT; ADYNAMIC BONE DISEASE; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE DISEASE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HEMODIALYSIS; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEITIS FIBROSA; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL;

AGED; BIOPSY; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMUR NECK; FIBROUS DYSPLASIA OF BONE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; NAPHTHALENES; PILOT PROJECTS; RENAL DIALYSIS; RISK; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84865590891     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000341864     Document Type: Article

References (28)

1. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.
2. Coco M, Rush DN: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121.
3. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366.
4. Mittalhenkle A, Gillen DL, Stehman-Breen CO: Increased risk of mortality associated with hip fractures in the dialysis population. Am J Kidney Dis 2004; 44: 672-679.
5. Jamal SA, Hodsman AB: Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues? Semin Dial 2011; 24: 12-15.
6. Cunningham J, Sprague SM: Osteoporosis in chronic kidney disease. Am J Kidney Dis 2004; 43: 566-571.
7. Miller PD: Treatment of Osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005; 3: 5-12.
8. Ott SM: Review article: Bone density in patients with chronic kidney disease stages 4-5. Nephrology (Carlton) 2009; 14: 395-403.
9. Elder GJ, Mackun K: 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 2006; 21: 1778-1784.
10. Jamal SA, Hayden JA, Beyene J: Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49: 674-681.
11. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y: Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 2005; 76: 256-260.
12. Kaji H, Suzuki M, Yano S, Sugimoto T, Chihara K, Hattori S, Sekita K: Risk factors for hip fracture in hemodialysis patients. Am J Nephrol 2002; 22: 325-331.
13. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N: A reference standard for the description of osteoporosis. Bone 2008; 42: 467-475.
14. Coen G, Mazzaferro S, Ballanti P, Chicca S, Manni M, Bonucci E, Taggi F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996; 11: 813-819.
15. Bergner R, Dill K, Boerner D, Uppenkamp M: Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study. Nephrol Dial Transplant 2002; 17: 1281-1285.
16. Lien YHH, Silva AL, Whittman D: Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1232-1237.
17. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
18. Malluche HH, Monier-Faugere MC, Wang G, Fraza JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG: An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69: 269-278.
19. Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E: Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298:F1315-F1322.
20. Nguyen-Yamamoto L, Bolivar I, Strugnell SA, Goltzman D: Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J Am Soc Nephrol 2010; 21: 1713-1723.
21. Peacock M, Bolognese MA, Borofsky M, Cumpia S, Sterling LR, Cheng S, Shoback D: Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867.
22. Norman J, Lopez J, Politz D: Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use. Ann Surg Oncol 2012; 19: 1466-1471.
23. Huraib S, Abu-Aisha H, Abed J, Al Wakeel J, Al Desouki M, Memon N: Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients. Am J Nephrol 1997; 17: 118-123.
24. Nakane M, Fey TA, Dixon DB, Ma J, Brune ME, Li YC, Wu-Wong JR: Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol 2006; 98: 72-77.
25. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynnski WP, Orwoll E, Yuen CK: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703.
26. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Chapter 4.3. Kidney Int 2009; 76(suppl 113):S90-S99.
27. Cejka D, Kodras K, Bader T, Haas M: Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press Res 2010; 33: 221-226.
28. Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 2008; 21: 510-516.